If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Aptar Pharma launches eDose counter for MDIs integrating a proprietary sensing technology

    • Aptar Pharma

    Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, will unveil its latest innovation, the eDose Counter for metered dose inhalers (MDIs), at the RDD scientific conference in Phoenix, Arizona from April 18-21, 2016.

    Dose Counters improve Asthma and C.O.P.D. patient adherence Asthma and COPD patient adherence is a major health and economic challenge. Several studies report very poor adherence to asthma medication regimens, with measured rates of non-adherence ranging from 30 to 70 percent.

    In the FDA’s Integration of Dose-Counting Mechanisms into MDI Drug Products guidance for industry, dated March 2003, it is recommended that drug manufacturers integrate a dose-counting system into any new MDI drug products marketed in the US.

    Patients appreciate dose counters because they are convenient and improve safety by allowing them to identify the number of doses of medication left in their inhalers and to avoid running out unexpectedly. The global inhalation market has followed the US trend and today multiple MDI drug products with some form of dose-tracking system are marketed outside of the US - including Skye Pharma’s Flutiform® equipped with Aptar Pharma’s Landmak® dose indicator.

    Electronic Dose Counters offer enhanced performance

    Currently, marketed MDI dose indicators and counters are based on mechanical technology. Although this technology offers great opportunities to design simple and cost-effective devices, it does not always meet the expectations of users, regulators and other stakeholders due to poor legibility of the numbers, its effect on MDI user-handling and pharma performance, and the lack of robustness impacting safety (e.g. miscounting events).

    Electronic components offer almost unlimited possibilities to display large, clear and legible counter digits required for a wide range of user age segments and medical conditions. In addition, this technology allows for the incorporation of visual MDI priming reminders and feedback on use as well as end-of-product-life warnings. Thanks to the integration of electronic components, these systems not only count doses, but mark a move towards comprehensive connected inhaler solutions.

    Aptar Pharma’s eDose Counter for MDIs integrates a unique sensing technology MDIs are complex systems that integrate several components such as the metering valve, the canister and the actuator. These components must be carefully designed and manufactured to ensure they work together effectively. This is particularly true for the valve and the dose counter. As the world leading supplier of MDI valves, Aptar Pharma’s expertise and experience enables a smooth integration of all MDI components, including the dose counter.

    Our patented eDose Counter for MDIs is designed to be easy-to-use and reliable, and contributes to patient compliance. Our unique sensing technology offers direct detection of the spray which eliminates risks of miscounting. The sensing technology is versatile and compatible with any metering valve design. In addition, our eDose Counter for MDIs includes inhaler priming and medication reminders-to-use and end-of-product-life warnings (flashing digits) while remaining cost-effective.

    “Aptar Pharma is very pleased to launch our novel electronic Dose Counter for MDIs. We believe the combination of Aptar Pharma’s expertise in MDI valves and dose counters with our experience in electronically-assisted drug delivery devices creates a compelling offer to meet the needs of Asthma & CODP patients”, commented Jean-Marc Pardonge, President of Aptar Pharma Prescription Division.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Frank Robledano Espín
    • Product Info
    • English
    • Created 19 Apr 2016
    • Modified 05 Jul 2018
    • Hits 1632